Sunday May 27, 2018 20:49

Heathcare Press Release : 02 Mar 2017

NICE Expands Positive Recommendation for Erbitux as First-line Treatment for RAS Wild-type Heathcare—02 Mar 17

- More patients now able to receive a standard-of-care treatment with Erbitux plus FOLFIRI or FOLFOX - NICE's recommendation is a significant step forward in Merck's aspiration to ensure cancer patients have optimal access to effective treatments